TY - JOUR
T1 - A Novel Scoring System Based on Fibrinogen and the Neutrophil-Lymphocyte Ratio as a Predictor of Chemotherapy Response and Prognosis in Patients with Advanced Gastric Cancer
AU - Arigami, Takaaki
AU - Uenosono, Yoshikazu
AU - Ishigami, Sumiya
AU - Okubo, Keishi
AU - Kijima, Takashi
AU - Yanagita, Shigehiro
AU - Okumura, Hiroshi
AU - Uchikado, Yasuto
AU - Kijima, Yuko
AU - Nakajo, Akihiro
AU - Kurahara, Hiroshi
AU - Kita, Yoshiaki
AU - Mori, Shinichiro
AU - Maemura, Kosei
AU - Natsugoe, Shoji
N1 - Publisher Copyright:
© 2016 S. Karger AG, Basel.
PY - 2016/4/1
Y1 - 2016/4/1
N2 - Objective: We assessed the clinical applicability of the F-NLR score, which is based on fibrinogen (F) and the neutrophil-lymphocyte ratio (NLR), and the Glasgow Prognostic Score (GPS) to predict the therapeutic effects of chemotherapy or chemoradiotherapy on advanced gastric cancer and the prognoses of patients. Methods: Sixty-eight patients with advanced gastric cancer treated with first-line chemotherapy or chemoradiotherapy were classified into two groups based on tumor response. Furthermore, we categorized patients according to cutoff F-NLR scores of 2 [hyperfibrinogenemia (>400 mg/dl) and high NLR (>3.0)], 1 [one of these hematological abnormalities], and 0 [neither hyperfibrinogenemia nor high NLR]. Results: A total of 27 patients had progressive disease (PD) and 41 did not. The F-NLR scores were significantly higher in the PD than in the non-PD group (p = 0.003). Survival was significantly shorter for patients with high F-NLR scores and GPS (p = 0.0071 and p = 0.0065, respectively). Multivariate analysis selected the F-NLR score as an independent prognostic factor (p = 0.017). Conclusion: A novel grading system based on F-NLR scores, as well as the GPS, appears to have value as a clinical predictor of the therapeutic response of advanced gastric cancer to chemotherapy or chemoradiotherapy and the prognoses of patients.
AB - Objective: We assessed the clinical applicability of the F-NLR score, which is based on fibrinogen (F) and the neutrophil-lymphocyte ratio (NLR), and the Glasgow Prognostic Score (GPS) to predict the therapeutic effects of chemotherapy or chemoradiotherapy on advanced gastric cancer and the prognoses of patients. Methods: Sixty-eight patients with advanced gastric cancer treated with first-line chemotherapy or chemoradiotherapy were classified into two groups based on tumor response. Furthermore, we categorized patients according to cutoff F-NLR scores of 2 [hyperfibrinogenemia (>400 mg/dl) and high NLR (>3.0)], 1 [one of these hematological abnormalities], and 0 [neither hyperfibrinogenemia nor high NLR]. Results: A total of 27 patients had progressive disease (PD) and 41 did not. The F-NLR scores were significantly higher in the PD than in the non-PD group (p = 0.003). Survival was significantly shorter for patients with high F-NLR scores and GPS (p = 0.0071 and p = 0.0065, respectively). Multivariate analysis selected the F-NLR score as an independent prognostic factor (p = 0.017). Conclusion: A novel grading system based on F-NLR scores, as well as the GPS, appears to have value as a clinical predictor of the therapeutic response of advanced gastric cancer to chemotherapy or chemoradiotherapy and the prognoses of patients.
UR - http://www.scopus.com/inward/record.url?scp=84961233944&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84961233944&partnerID=8YFLogxK
U2 - 10.1159/000444494
DO - 10.1159/000444494
M3 - Article
C2 - 26981856
AN - SCOPUS:84961233944
SN - 0030-2414
VL - 90
SP - 186
EP - 192
JO - Oncology (Switzerland)
JF - Oncology (Switzerland)
IS - 4
ER -
